Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Shire and Novimmune sign license agreement for bispecific antibody for hemophilia A

July 19, 2017

Phase III results for emicizumab prophylaxis in patients with hemophilia A with inhibitors presented

July 19, 2017

Julius-Maximilians-Universitaet Wuerzburg divulges polypeptides for thrombotic disorders

July 18, 2017

EMA committee recommends approval of label update for Lixiana

July 17, 2017

Bayer tests novel thrombin inhibitor BAY-224 in thrombosis models

July 14, 2017

Vifor Pharma begins three studies in iron deficiency and heart failure

July 14, 2017

Shire develops enhanced factor IX gene therapy

July 13, 2017

First-in-human study finds TFPI inhibitor PF-06741086 well tolerated

July 12, 2017

MedigenixBio tests new antithrombotic compound MDI-2001 in vivo

July 12, 2017

Global Blood Therapeutics expands phase IIa study of GBT-440

July 11, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...